Prostate Cancer Clinical Trial
Effect of Weight Loss on Prostate Cancer Pathology
Summary
The purpose of this study is to determine if weight loss prior to radical prostatectomy effects chemical substances in the blood stream and prostate tissue that may affect prostate cancer development and progression.
Full Description
Obesity is an epidemic, a major public health concern, and is a significant risk factor for progression and mortality from prostate cancer. Prior work in the investigators' laboratory in pre-clinical prostate cancer models and in obese men found that a low fat diet, exercise, and weight loss resulted in antiproliferative and pro-apoptotic effects on prostate cancer tissue through mechanisms related to the IGF-axis. The investigators now propose to conduct a prospective, randomized clinical trial in overweight and obese men with prostate cancer undergoing radical prostatectomy to evaluate if weight loss prior to radical prostatectomy results in antiproliferative and pro-apoptotic effects in prostate cancer tissue. The investigators will accomplish this aim by enrolling overweight and obese men with prostate cancer scheduled to undergo radical prostatectomy. Following informed consent, men will be randomized to either immediate radical prostatectomy or to an 8-week weight loss intervention group that will undergo a diet and exercise weight loss program followed by radical prostatectomy. Proliferation and apoptosis of prostate cancer cells in the prostatectomy specimen will be compared between the groups and relative to the baseline prostate needle biopsy specimens. Further studies will evaluate potential serum surrogate biomarkers that the investigators developed in the investigators' laboratory (ex-vivo serum bioassays) and serum and tissue IGF-axis proteins that have previously been related to obesity, weight loss, and prostate cancer progression. The goal of the investigators' project will be to evaluate the potential anticancer effects of weight loss on prostate cancer tissue and to identify surrogate serum biomarkers that reflect antiproliferative and pro-apoptotic tissue effects and can be applied to future secondary prevention trials in overweight and obese prostate cancer survivors.
Eligibility Criteria
Inclusion Criteria:
Subject is overweight or obese (BMI > 25 kg/m2)
Patient with pathologically confirmed adenocarcinoma of the prostate and has elected to undergo radical prostatectomy
Willing to delay radical prostatectomy for 5 to 8-weeks if randomized to the weight loss intervention group.
Able to adhere to physical activity intervention (able to walk for 30 minutes without rest)
Able to come to the VA for weight loss visits during the 5 to 8-wk study
Exclusion Criteria:
Any one of the following: Gleason grade > 4+4, PSA > 20.
History of ever receiving androgen deprivation therapy, antiandrogen therapy, or finasteride
Prior prostate radiotherapy (external beam or brachytherapy) or prior cryotherapy
Diagnosis of diabetes mellitus and on insulin**
Current use of weight loss medications or enrolled in a diet/weight loss program
Current use of lycopene supplements*** Significant co-morbidities (i.e. cardiac, pulmonary, liver disease, ongoing alcohol/drug abuse) Cardiac pacemaker
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
West Los Angeles California, 90073, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.